Bioaltus
Bioaltus Pharmaceuticals is a privately held Indian third-party pharmaceutical contract manufacturer founded in 2014, operating three cGMP-WHO certified plants that produce finished formulations across 10+ therapeutic areas for 1000+ brand clients domestically and in select export markets.
- Company typePrivate
- Founded2014
- HeadquartersThane, India
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bioaltus does
Bioaltus Pharmaceuticals Pvt. Ltd. is an India-based, privately held third-party pharmaceutical contract manufacturer founded in March 2014 and headquartered in Thane (Mumbai), operating three manufacturing facilities in Maharashtra, Himachal Pradesh (Baddi), and Gujarat (Valsad). The company produces finished formulations across multiple dosage forms — tablets, capsules, syrups, suspensions, soft gelatin capsules, dry powder injections, and nutraceuticals — spanning 10+ therapeutic categories including diabetology, cardiology, nephrology, urology, gastrology, neuropathic/pain, respiratory, multivitamin, and critical care. Its core technology platform consists of cGMP-WHO certified manufacturing processes, with proprietary iMickro and iMickro Nano formulation technologies protected by IPR that target enhanced bioavailability.
The business model is a B2B contract-manufacturing transaction-fee structure: Bioaltus manufactures on behalf of pharmaceutical brand clients and is paid on a per-order basis determined by formulation complexity, batch size, and regulatory requirements. It serves a distributed base of 1000+ clients and 8000+ brand partners, ranging from early-stage pharma startups needing small batches and formulation guidance to large Indian pharma companies (Cipla, Intas, Cadila, Wockhardt, Micro Labs, Aristo, Eris, Leeford, Systopic, Dr. Morepen) requiring large-scale commercial production. A second revenue stream runs through an Institutional Division that supplies corporate hospitals, public hospitals, and Central/State/PSU healthcare organizations in India, and a third stream covers international exports to Venezuela, Africa, Latin America, SAARC, and CIS regions.
Go-to-market relies on enterprise field sales direct to pharma brand clients, event-driven lead generation at CPHI India, PharmmaEx, and IPHEX exhibitions, and a digital presence spanning a content-marketing blog, LinkedIn, Instagram, Facebook, and WhatsApp Business. The company is investing in a new manufacturing facility dedicated to regulated international markets (US FDA, EMEA, ANVISA, PMDA, KFDA, COFEPRIS compliance), which is the principal forward-looking capital and capability commitment visible in the data. Bioaltus is founder-owned, with Ankit Varshney as Founder and Director, and has no disclosed external institutional or private equity investment.
Bioaltus firmographics
Firmographics- Name
- Bioaltus
- Legal name
- Bioaltus Pharmaceuticals Pvt. Ltd.
- Website
- https://bioaltus.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Bioaltus Pharmaceuticals is a privately held Indian third-party pharmaceutical contract manufacturer founded in 2014, operating three cGMP-WHO certified plants that produce finished formulations across 10+ therapeutic areas for 1000+ brand clients domestically and in select export markets.
- Ownership category
- akta.pro rank
Where Bioaltus is headquartered
LocationHeadquarters
- HQ city
- Thane
- HQ country
- India
- HQ region
- Asia
Offices3 records
Markets served
Bioaltus business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Manufacturing Services: Third-party pharmaceutical manufacturing services where Bioaltus manufactures products on behalf of pharma brands. Revenue is generated through production fees based on order volume and formulation complexity. They serve both startups (small batches) and established brands (large-scale production).
- Institutional Supply: Supply of pharmaceutical formulations to hospitals, corporate institutions, government/PSU healthcare organizations, and public health infrastructure
- International Business / Export: Export of high-efficacy pharmaceutical formulations to international markets including Venezuela, Africa, Latin America, SAARC, and CIS regions. Revenue generated from international product sales.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Bioaltus product offering
Product offeringCore offering
Bioaltus is a third-party pharmaceutical contract manufacturer that produces finished formulations including tablets, capsules, syrups, suspensions, soft gelatin capsules, dry powder injections, and nutraceuticals for pharma brand clients and institutional buyers. The company offers end-to-end services from formulation development and small-batch production for market testing to large-scale commercial manufacturing, private labeling, and packaging development at cGMP-WHO certified facilities in India. It also supplies pharmaceutical formulations directly to corporate hospitals and government healthcare organizations through its institutional division.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Serving 1000+ satisfied clients and 8000+ brand partners
Companies that use Bioaltus
Customer profileNamed customers12 records
Segments4 records
Ideal customer profiles4 records
Bioaltus technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Bioaltus partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Regulated Market PartnerscoreBioaltus is in the process of setting up a new manufacturing facility dedicated to regulated international business (US FDA, EMEA, ANVISA, PMDA, KFDA, COFEPRIS compliant), targeting markets in Venezuela, Africa, Latin America, SAARC, and CIS regions.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Bioaltus competitors and assessment
Company assessmentDirect peers
- Syngene International: Syngene International is India's largest listed CRO/CDMO with formulation development and manufacturing capabilities — directly comparable to Bioaltus as an Indian contract services provider, though more research-weighted and substantially larger.
- Granules India: Granules India is an Indian pharmaceutical manufacturer operating across APIs, intermediates, and finished dosages with significant contract-manufacturing exposure — a directly comparable small/mid-cap Indian formulations manufacturer with overlapping customer-base dynamics.
- Neuland Laboratories: Neuland Laboratories is an Indian CDMO specializing in APIs and intermediates with custom synthesis services — directly comparable to Bioaltus as a mid-sized Indian contract manufacturer with multi-decade track records serving branded pharma customers.
- Piramal Pharma Solutions: Piramal Pharma Solutions is the contract development and manufacturing arm of the Piramal Group, offering finished-dosage and injectable manufacturing services — comparable to Bioaltus in service scope, though at significantly larger scale and with global regulatory positioning.
- Sai Life Sciences: Sai Life Sciences is an Indian CDMO providing API, intermediate, and formulation services to global pharma and biotech customers — directly comparable to Bioaltus as an Indian contract manufacturer with similar customer-base dynamics and scope across dosage forms.
- Suven Pharmaceuticals: Suven Pharmaceuticals is an Indian CRAMS/CDMO providing contract manufacturing and drug-delivery services to global pharma companies — directly comparable to Bioaltus as an Indian mid-sized contract manufacturer serving pharma brands domestically and internationally.
Broad incumbents
- Divis Laboratories: Divis Laboratories is one of India's largest API manufacturers with a meaningful CDMO business serving global generic and innovator customers — a broad incumbent comparable to Bioaltus's contract-manufacturing services but operating at substantially larger scale and a different mix toward APIs.
- Aurobindo Pharma: Aurobindo Pharma is a global Indian generic pharmaceutical manufacturer that also engages in third-party/contract manufacturing — broad incumbent with overlapping dosage-form capabilities but at much larger scale and a different customer base (its own brands plus global generics).
- Lonza Group: Lonza Group is a Swiss-headquartered global CDMO providing contract manufacturing across small molecules, biologics, and cell & gene therapies — a broad incumbent adjacent to Bioaltus's finished-dosage CDMO scope, operating globally at vastly larger scale with a more diversified service portfolio.
- Catalent: Catalent is a large global CDMO providing formulation, finished-dosage, and sterile injectable contract manufacturing — a broad incumbent in the same broader space as Bioaltus, serving global pharma customers with similar services but at much greater scale and globally diversified footprints.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Bioaltus social profiles
Digital presenceBioaltus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bioaltus leadership team
Management profileNumber of profiles
Profiles1 record
Bioaltus funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bioaltus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bioaltus
What does Bioaltus do?
Bioaltus is a third-party pharmaceutical contract manufacturer that produces finished formulations including tablets, capsules, syrups, suspensions, soft gelatin capsules, dry powder injections, and nutraceuticals for pharma brand clients and institutional buyers. The company offers end-to-end services from formulation development and small-batch production for market testing to large-scale commercial manufacturing, private labeling, and packaging development at cGMP-WHO certified facilities in India. It also supplies pharmaceutical formulations directly to corporate hospitals and government healthcare organizations through its institutional division.
Is Bioaltus a public or private company?
Bioaltus is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Bioaltus founded?
Bioaltus was founded in 2014. It employs 51 to 100 people.
Where is Bioaltus based?
Bioaltus is headquartered in Thane, India, in the Asia region.
How does Bioaltus make money?
Three revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are institutional Supply and international Business / Export.
Who are Bioaltus's main competitors?
Direct peers on record are Syngene International, Granules India, Neuland Laboratories, Piramal Pharma Solutions, Sai Life Sciences and Suven Pharmaceuticals. Broad incumbents are Divis Laboratories, Aurobindo Pharma, Lonza Group and Catalent.
Does Bioaltus have an API?
No public API is recorded for Bioaltus.